Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection.

IF 3.6 3区 医学 Q2 PHARMACOLOGY & PHARMACY Pharmacopsychiatry Pub Date : 2024-07-01 Epub Date: 2024-03-26 DOI:10.1055/a-2286-1427
Yuna Takahashi, Taisuke Yatomi, Naohito Yamaguchi, Kimio Yoshimura, Satoko Hori, Hiroyuki Uchida
{"title":"Comparable Psychotropic Prescription Rates After Hospital Discharge Between Patients with COVID-19 and Those With Non-COVID-19-Related Respiratory Infection.","authors":"Yuna Takahashi, Taisuke Yatomi, Naohito Yamaguchi, Kimio Yoshimura, Satoko Hori, Hiroyuki Uchida","doi":"10.1055/a-2286-1427","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Whether psychiatric symptoms after recovery from coronavirus disease 2019 (COVID-19) are specific to this illness remains unclear.</p><p><strong>Methods: </strong>In this retrospective study, the Diagnosis Procedure Combination data and outpatient clinic data were used for patients who received inpatient treatment in Saiseikai-affiliated hospitals for COVID-19 or other respiratory tract infections (non-COVID) from 2020 to 2022. The primary outcome was new prescriptions of psychotropic drugs after discharge (i. e., prescriptions of psychotropics to patients who had not received them before or during their hospitalization). Values of interest were compared between groups using the chi-square test or Fisher's exact test. A COX proportional-hazards model was used to examine factors associated with psychotropic prescriptions after discharge in age- and sex-matched COVID-19 and non-COVID patients.</p><p><strong>Results: </strong>Of 31,993 chart records, 19,613 were excluded due to a positive history with psychiatric disorders (n=2,445), prescriptions of psychotropics (n=744), and no follow-ups (n=16,424). Thus, 3,648 COVID-19 and 8,732 non-COVID patients were included (mean [range] duration of follow-up, days: 146.9 [1-727] and 239.2 [1-729], respectively). Two hundred and four (5.6%) of the 3,648 patients with COVID-19 received psychotropic prescriptions after discharge. No statistically significant differences were observed in the prescription rates of any psychotropic category between the COVID-19 and non-COVID groups. An increase in severity during hospitalization was significantly associated with more frequent psychotropic prescriptions (hazard ratio 1.83, p<0.001).</p><p><strong>Discussion: </strong>The development of psychiatric symptoms should be closely observed, especially in patients who experienced increased severity during hospitalization, regardless of whether they suffered from COVID-19.</p>","PeriodicalId":19783,"journal":{"name":"Pharmacopsychiatry","volume":" ","pages":"186-190"},"PeriodicalIF":3.6000,"publicationDate":"2024-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmacopsychiatry","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2286-1427","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/26 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Whether psychiatric symptoms after recovery from coronavirus disease 2019 (COVID-19) are specific to this illness remains unclear.

Methods: In this retrospective study, the Diagnosis Procedure Combination data and outpatient clinic data were used for patients who received inpatient treatment in Saiseikai-affiliated hospitals for COVID-19 or other respiratory tract infections (non-COVID) from 2020 to 2022. The primary outcome was new prescriptions of psychotropic drugs after discharge (i. e., prescriptions of psychotropics to patients who had not received them before or during their hospitalization). Values of interest were compared between groups using the chi-square test or Fisher's exact test. A COX proportional-hazards model was used to examine factors associated with psychotropic prescriptions after discharge in age- and sex-matched COVID-19 and non-COVID patients.

Results: Of 31,993 chart records, 19,613 were excluded due to a positive history with psychiatric disorders (n=2,445), prescriptions of psychotropics (n=744), and no follow-ups (n=16,424). Thus, 3,648 COVID-19 and 8,732 non-COVID patients were included (mean [range] duration of follow-up, days: 146.9 [1-727] and 239.2 [1-729], respectively). Two hundred and four (5.6%) of the 3,648 patients with COVID-19 received psychotropic prescriptions after discharge. No statistically significant differences were observed in the prescription rates of any psychotropic category between the COVID-19 and non-COVID groups. An increase in severity during hospitalization was significantly associated with more frequent psychotropic prescriptions (hazard ratio 1.83, p<0.001).

Discussion: The development of psychiatric symptoms should be closely observed, especially in patients who experienced increased severity during hospitalization, regardless of whether they suffered from COVID-19.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
COVID-19 和非 COVID-19 相关呼吸道感染患者出院后精神药物处方率相当。
简介:2019年冠状病毒病(COVID-19)康复后的精神症状是否具有特异性尚不清楚:2019年冠状病毒病(COVID-19)康复后的精神症状是否为该病所特有,目前仍不清楚:在这项回顾性研究中,使用了诊断程序组合数据和门诊数据,对象是2020年至2022年期间因COVID-19或其他呼吸道感染(非COVID)而在济生会附属医院接受住院治疗的患者。主要结果是出院后新开具的精神药物处方(即向住院前或住院期间未接受过精神药物治疗的患者开具精神药物处方)。组间相关数值的比较采用卡方检验或费雪精确检验。采用 COX 比例危险度模型对年龄和性别匹配的 COVID-19 和非 COVID 患者出院后精神药物处方的相关因素进行了研究:在 31,993 份病历记录中,有 19,613 份因精神病史阳性(2,445 人)、精神药物处方(744 人)和未随访(16,424 人)而被排除。因此,共纳入了 3 648 名 COVID-19 和 8 732 名非 COVID 患者(平均[范围]随访时间,天数:146.9 [1-727] 天):分别为 146.9 [1-727] 天和 239.2 [1-729] 天)。在 3,648 名 COVID-19 患者中,有 24 人(5.6%)在出院后接受了精神药物处方治疗。COVID-19组和非COVID-19组的精神药物处方率在统计学上没有明显差异。住院期间病情严重程度的增加与更频繁的精神药物处方显著相关(危险比 1.83,p 讨论:无论患者是否患有 COVID-19,都应密切观察其精神症状的发展情况,尤其是住院期间病情加重的患者。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Pharmacopsychiatry
Pharmacopsychiatry 医学-精神病学
CiteScore
7.10
自引率
9.30%
发文量
54
审稿时长
6-12 weeks
期刊介绍: Covering advances in the fi eld of psychotropic drugs, Pharmaco psychiatry provides psychiatrists, neuroscientists and clinicians with key clinical insights and describes new avenues of research and treatment. The pharmacological and neurobiological bases of psychiatric disorders are discussed by presenting clinical and experimental research.
期刊最新文献
Impact of Parkinson Medication on Neuropsychiatric and Neurocognitive Symptoms in Patients with Advanced Parkinson Disease Prior to Deep Brain Stimulation. Impact of Antipsychotic Medications on Weight Gain and Eating Disorder-Related Psychopathology in Adult Inpatients with Anorexia Nervosa. Activation of Hippocampal Neuronal NADPH Oxidase NOX2 Promotes Depressive-Like Behaviour and Cognition Deficits in Chronic Restraint Stress Mouse Model. Early Treatment-Resistance in First Episode Psychosis. ABC Family Gene Polymorphisms and Cognitive Functions Interact to Influence Antidepressant Efficacy.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1